65,437 trials
Chronic Shoulder Pain
Primary: Change of Shoulder Pain and Disability Index (SPADI) — 22.1; 25.9; 27.0; 36.6 score on a scale
Discoid Lupus Erythematosus
Primary: Mean Severity of Disease as Measured by the Investigator's Global Assessment — 1.4 score on a scale
COVID-19
Primary: Number of Participants With Serious Adverse Events (SAEs) After Primary Dose — 16 Participants
Adverse Childhood Experiences
Primary: ACEs Screenings Reach — 0; 468; 73 Participants
Pain · Nausea · Anxiety
Primary: Perioperative Anxiety Expressed in Visual Analogue Scale for Anxiety (VAS-A) From 0 (Asymptomatic: no Anxiety) to 10 Extremely Symptomatic Anxiety — -2.83; 0.24; -1.99…
Crohns Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 33 Participants
Prevention of COVID-19
Primary: Antibody Titre Increase 14 Days After Study Vaccination Dose. — 100; 100; 78.46; 87.22 percentage of participants
Dementia · Med: Dementia
Primary: Medication Possession Ratio (MPR) for Any Antipsychotics Medication — 0.64; 0.56 Medication possession ratio
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0 participants
Fertility Issues
Primary: Total Number of Retrieved Oocytes — 13.33; 11.87 oocytes
Obesity · Risk Factors
Primary: Recruitment Rate — 101 Participants
Respiratory Syncytial Virus Infections
Primary: Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 Vaccination — 74.7; 110.8; 88.5; 116.2 Titers
Age-Related Sarcopenia · Muscle Loss
Primary: Double Leg Press Peak Power at 70% — 260.3; 255.6; 251.1; 264.8 Watts
Covid19
Primary: Solicited Administration Site Reactions — 19; 15; 20 participants
Colon Cancer
Primary: Progression Free Survival — 38; 34; 6; 3 Participants